conference Good and you today's call. Thank for joining for you, Melissa. thank us afternoon,
First expectations. quarter line in are results with our
pricing. were Revenues channel, results shift and achieved to XXXX. QX sequential balancing basis due pricing We a monitor highest primarily since gross by and of down product we our our slightly profitability. margin constantly QX, a strategic EBITDA access on During consumer in sales
is and growth of that will. want managed offering we One sales carefully also profitability product revenue with to investment by to revenue goals and we balance But mix. and certainly grow our we channel
are profitability Going forward, both several we growth about optimistic revenue and for reasons.
pandemic relief recovery. First, and
and BXB reopens more the As retail including normalized we channels. emerging, and channel a products economy traditional other see returns, for FDM, retail BXB natural
to in improvement retail with the see are believe economy as We now continued opens occur throughout XXXX conversations further. will this our starting and we partners,
digital traditional room Second, sales starting and we higher believe the there channel retail. margins with growth than significant is just for is
have last the good our Over made investments and our showing across been strengthen digital capabilities year, to platform results. are
visitors, all We average conversion value. site KPIs positive order seen trends including our have of in and
digital more digital stood including all have programs, permanent We robust pandemic initiatives shift behavior, of critical. has recognize affiliate, which that up progress. investment change and shopping We to SEO, accelerated and a showing our likely the ship a email, auto program social in excellent making are consumer media
channels offering Sciences We And starting. and is in we will pursuing. position to in sales important positioning continue third, this the our are to are channel we mentioned, just as CV needs for invest our platform I digital meet that evolve sales product consumer in growth to
back workplace. continue Sleep to for including to routines, that Calm the this of offering and week our normal for people natural to retail we this product response just We their PlusCBD product have always will the our evolve gummies channel for earlier including the reentry important healthy cycles channel stress and support and launch been sleep well-positioned getting
the for products the in for consumers for line natural new line, example controlled can several safety line which review. science-based backed high clinical that by to a significant with CBD science, by supported record introduced clinical sales on available post are including that channel We only with practitioner is ProCBD track January, be on a critically product investigations, barrier-to-entry our marketing Another in this desire channel. medical companies strength product be exclusively channel. and reasons, randomized using of this growth This ProCBD is market, studies, published A is alternatives. higher science for opportunity plant-based our which product see development strength much channel must discerning in has are by Also, the trusted. important and focus products
will and that become channel believe a we medical mix of are in practitioner component revenue We significant company, our the certainly future. the
preferences, states, will offering shopping evolve, demand. to need meet manage demographics consumer product consumer behaviors continuously we As and our
has believe will I for and XXXX, that year half our the of reopening, digital planning natural We new growth economy targeted expect will in but last available, see second We practitioner normalization and from we a benefit offering the been XXXX. half products the of including the market that the introduce digital product provide foundation to just half our second during are first sales difficult, continue in start to recognize targeted the of mentioned, forward. of And these investment, and evolving several initiatives mix. the and the XXXX products factors all medical channels. going to biggest opportunities We and believe for
Labs category. Sciences why month, testing Standards to of further last efforts with partnership measurement This testing established Technology, and company front, CBD capabilities with most and the improve and and labs National trusted in we botanical collaborate announced the science to science Alkemist Institute cannabis help CV an is leadership in in ongoing demonstrates comparability. leader the demonstrate the plant continued On
we for front, Congress the of a partner the continue regulatory lead with members and regulatory with to FDA the discussion On framework. sensible
a for and industry support the enforce. help including XXX, set and this We also are follow with of industry would rules help of accelerate contraction brand impact provide actors. of to and involved for clear rid current efforts, H.R. which to FDA would The legislative legislation bad
is program cessation advancing. drug Our nicotine development
toxicology which for planning activities are on support CMC late and planned our in XXXX focused currently or have chemistry, are pharmacological studies, We XXXX. and we early manufacturing or clinical controls of our completed studies,
mentioned, As the I and Japanese Patent of market, for notification the U.S. from in the have issuance Office patent approval for notice we XXXX, market. Japanese formal received from the previously USPTO
are actively other protection in patent We pursuing significant and select countries represent worldwide opportunities. market that geographies
believe We continue our for that significant to this hidden value represents program company.
the sometime mentioned As this to calls, in we in prior partner expect program future.
run Now, through to financials. turn Joerg it let to me our over